Some analyses and comment on the Dummit opinion from New York in July (a/k/a In re New York City Asbestos Litigation) is set out in an August 12, 2016 post at the Drug and Device blog. The blog is written by some of the best product liability lawyers for pharma. The post highlights the fact that product liability opinions on one setting (asbestos litigation) can have implications in other settings (pharma litigation). The asbestos section of the article closes as follows:
“This opinion is very bad news for the affected companies, who are now sucked into the maw of interminable asbestos litigation on the basis of products they didn’t even make, but it’s not bad at all for our prescription medical product manufacturer clients.”
Comments